How Nanotechnology Can Help Heal Hearts

Nanotechnology is especially suited to medicine because nature operates at not even a micro, but a nano scale synapses, the extracellular spaces between neurons that exchange massive amounts of information per second are approximately only 20-40 nanometres (nm) wide. The typical largest coronary artery, which supplies oxygen-rich blood to the heart, barely measures an inch in diameter.

Nanotechnology works with this natural nanoscale to deliver better healthcare results with fewer risks and side effects in a shorter span of time. It uses finer instruments, minimally invasive procedures and more efficient drug delivery systems to unblock blood vessels and repair tissues. This aspect of nanotechnology is especially useful and can reduce the risks associated with many invasive procedures, including cardiac care protocols.

Angioplasty is a procedure to open narrowed or blocked coronary arteries, which supply blood to the heart. During an angioplasty, a balloon catheter is guided into the affected artery; the balloon may be ‘blown up’ a few times to widen the diameter of the artery. Often a coronary artery stent, a small, metal mesh tube that expands inside the artery, is placed during or immediately after angioplasty to help prevent the artery from closing up again. A drug-eluting stent, now the norm, has medicine embedded in it that helps prevent the artery from closing in the long-term.

So far, so good. But this is where we run into a hiccup.  One of the biggest problems with current drug-eluting stents is Paclitaxel, the very drug they carry. Clinical trials show toxicity associated with Paclitaxel and increased chances of thrombosis, a dangerous event linked with heart attacks and strokes. Cardiologists remain conflicted over the use of Paclitaxel. A possible solution to Paclitaxel could be an alternate, safer drug, which is small enough at the molecular level to be bioavailable and can also be introduced in the artery in a short span of 35-40 seconds. Keep the stent in the artery any longer than this razor-thin span and you risk complications. Sirolimous is one such drug, but the biggest problem with Sirolimous is that it is slow on the uptake.

It took years of research by a dedicated core team of doctors, surgeons, pharmacists and chemists to finally put together the puzzle. And when all the pieces locked in place, the answer was perfect in its simplicity – a nanotechnology-enabled polymer-free drug-eluting stent system, especially adapted to carry Sirolimous, a far safer and hypoallergenic drug than Paclitaxel.

Source: https://yourstory.com/